Taiho Pharmaceutical and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy met its primary progression-free survival endpoint at an interim analysis. The study was halted early for efficacy in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer. This success positions zipalertinib to challenge established treatments like Johnson & Johnson's Rybrevant and AstraZeneca's Zegfrovy in a highly competitive market.
REZILIENT3 phase 3 results
- ▪Taiho Pharmaceutical and Cullinan Therapeutics announced on August 12, 2026, that their investigational EGFR inhibitor zipalertinib combined with chemotherapy met its primary endpoint of progression-free survival in the Phase 3 REZILIENT3 trial.
- ▪The safety profile for the zipalertinib and chemotherapy combination arm in the REZILIENT3 trial was reported as manageable by Taiho Pharmaceutical and Cullinan Therapeutics.
- ▪An independent data committee recommended unblinding the REZILIENT3 trial at a planned interim analysis due to the statistically significant and clinically meaningful magnitude of progression-free survival improvement.
EGFR exon 20 mutations
- ▪The prevalence of EGFR exon 20 insertion mutations is estimated to be higher among patients in China, women, and non-smokers.
- ▪Epidermal growth factor receptor (EGFR) exon 20 insertion mutations account for approximately 1% to 10% of the 10% to 15% of lung tumors in the United States that harbor EGFR mutations.
Hazard ratio comparison
- ▪The REZILIENT3 trial was powered to detect a hazard ratio of 0.60 at 90% power, suggesting to analysts that the interim analysis achieved a hazard ratio below 0.60 to meet stopping criteria.
- ▪Dizal Pharmaceutical and AstraZeneca's EGFR inhibitor Zegfrovy demonstrated a hazard ratio of 0.65, representing a 35% improvement in progression-free survival, in its Phase 3 first-line trial.
Competitive EGFR inhibitor market
- ▪ArriVent BioPharma is expecting Phase 3 clinical trial data for its competing EGFR inhibitor firmonertinib in the second half of 2026.
- ▪AstraZeneca acquired global commercialization rights to Dizal Pharmaceutical's Zegfrovy for $600 million upfront and up to $1.5 billion in total payments.
- ▪If approved, zipalertinib combined with chemotherapy would compete in the first-line setting with Johnson & Johnson's Rybrevant plus chemotherapy and Dizal Pharmaceutical's Zegfrovy.
FDA regulatory review status
- ▪Taiho Pharmaceutical and Cullinan Therapeutics plan to seek regulatory approval for zipalertinib combined with chemotherapy in the first-line setting based on the REZILIENT3 results.
- ▪The Food and Drug Administration is currently reviewing zipalertinib as a second-line monotherapy for previously treated EGFR exon 20 non-small cell lung cancer, with a decision deadline of February 27, 2027.
Story comments
Loading comments…